Y. Cheng

机构：Jilin Province Tumor Hospital, Anhui Provincial Hospital · ORCID：0009-0007-4791-0051

发表论文 24 篇 · 总被引 168 次 · h-index 8

代表论文

• Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study (2018 · Annals of Oncology · 被引 40)
• Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway (2023 · Journal for ImmunoTherapy of Cancer · 被引 22)
• 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC) (2022 · Annals of Oncology · 被引 16)
• LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial (2022 · Annals of Oncology · 被引 15)
• LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial (2024 · Annals of Oncology · 被引 14)
• 2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC (2022 · Annals of Oncology · 被引 12)